Market Research Logo

Optic Nerve Disorders Drug Development Pipeline Review, 2018

Optic Nerve Disorders Drug Development Pipeline Review, 2018

Summary


Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 10 products in development for this indication.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye. There are 13 products in development for this indication.

LHON is an inherited form of vision loss. This condition usually begins in a person’s teens or twenties. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 16 products in development for this indication.

Optic neuritis refers to inflammation of the optic nerve. Symptoms include pain, vision loss, dyschromatopsia (impaired ability to perceive colors) and flashing lights. There are 12 products in development for this indication.

Molecular targets acted on by products in development for optic nerve disorders include kinases, growth factors and cannabinoid receptors. Companies operating in this pipeline space include NicOx SA Regeneron Pharmaceuticals and Amgen

This report “Optic Nerve Disorders Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for optic neuropathy, glaucoma, Leber’s hereditary optic neuropathy (LHON) and optic neuritis, and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Optic Nerve Disorders Report Coverage
    • Optic Neuropathy – Overview
    • Glaucoma – Overview
    • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Overview
    • Optic Neuritis – Overview
  • Therapeutics Development
    • Optic Neuropathy
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Optic Neuropathy
        • Table Number of Products under Development for Optic Neuropathy
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies, Optic Neuropathy
        • Table Number of Products under Development by Companies, Optic Neuropathy
      • Pipeline by Universities/Institutes
        • Table Number of Products under Development by Universities/Institutes, Optic Neuropathy
      • Products under Development by Companies
        • Table Products under Development by Companies, Optic Neuropathy
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Optic Neuropathy
    • Glaucoma
      • Pipeline Overview
        • Table Figure 3: Number of Products under Development for Glaucoma
        • Table Number of Products under Development for Glaucoma
      • Pipeline by Companies
        • Table Figure 4: Number of Products under Development by Companies, Glaucoma
        • Table Number of Products under Development by Companies, Glaucoma
      • Pipeline by Universities/Institutes
        • Table Figure 5: Number of Products under Development by Universities/Institutes, Glaucoma
        • Table Number of Products under Development by Universities/Institutes, Glaucoma
      • Products under Development by Companies
        • Table Products under Development by Companies, Glaucoma
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Glaucoma
    • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Pipeline Overview
        • Table Figure 6: Number of Products under Development for Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
        • Table Number of Products under Development for Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Pipeline by Companies
        • Table Figure 7: Number of Products under Development by Companies, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
        • Table Number of Products under Development by Companies, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Pipeline by Universities/Institutes
        • Table Number of Products under Development by Universities/Institutes, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Products under Development by Companies
        • Table Products under Development by Companies, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
    • Optic Neuritis
      • Pipeline Overview
        • Table Figure 8: Number of Products under Development for Optic Neuritis
        • Table Number of Products under Development for Optic Neuritis
      • Pipeline by Companies
        • Table Figure 9: Number of Products under Development by Companies, Optic Neuritis
        • Table Number of Products under Development by Companies, Optic Neuritis
      • Pipeline by Universities/Institutes
        • Table Number of Products under Development by Universities/Institutes, Optic Neuritis
      • Products under Development by Companies
        • Table Products under Development by Companies, Optic Neuritis
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Optic Neuritis
  • Therapeutics Assessment
    • Optic Neuropathy
      • Assessment by Target
        • Table Figure 10: Number of Products by Top 10 Targets, Optic Neuropathy
        • Table Figure 11: Number of Products by Stage and Top 10 Targets, Optic Neuropathy
        • Table Number of Products by Stage and Target, Optic Neuropathy
      • Assessment by Mechanism of Action
        • Table Figure 12: Number of Products by Top 10 Mechanism of Actions, Optic Neuropathy
        • Table Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Optic Neuropathy
        • Table Number of Products by Stage and Mechanism of Action, Optic Neuropathy
      • Assessment by Route of Administration
        • Table Figure 14: Number of Products by Routes of Administration, Optic Neuropathy
        • Table Figure 15: Number of Products by Stage and Routes of Administration, Optic Neuropathy
        • Table Number of Products by Stage and Route of Administration, Optic Neuropathy
      • Assessment by Molecule Type
        • Table Figure 16: Number of Products by Molecule Types, Optic Neuropathy
        • Table Figure 17: Number of Products by Stage and Molecule Types, Optic Neuropathy
        • Table Number of Products by Stage and Molecule Type, Optic Neuropathy
    • Glaucoma
      • Assessment by Target
        • Table Figure 18: Number of Products by Top 10 Targets, Glaucoma
        • Table Figure 19: Number of Products by Stage and Top 10 Targets, Glaucoma
        • Table Number of Products by Stage and Target, Glaucoma
      • Assessment by Mechanism of Action
        • Table Figure 20: Number of Products by Top 10 Mechanism of Actions, Glaucoma
        • Table Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Glaucoma
        • Table Number of Products by Stage and Mechanism of Action, Glaucoma
      • Assessment by Route of Administration
        • Table Figure 22: Number of Products by Routes of Administration, Glaucoma
        • Table Figure 23: Number of Products by Stage and Routes of Administration, Glaucoma
        • Table Number of Products by Stage and Route of Administration, Glaucoma
      • Assessment by Molecule Type
        • Table Figure 24: Number of Products by Top 10 Molecule Types, Glaucoma
        • Table Figure 25: Number of Products by Stage and Top 10 Molecule Types, Glaucoma
        • Table Number of Products by Stage and Molecule Type, Glaucoma
    • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Assessment by Target
        • Table Figure 26: Number of Products by Targets, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
        • Table Figure 27: Number of Products by Stage and Targets, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
        • Table Number of Products by Stage and Target, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Assessment by Mechanism of Action
        • Table Figure 28: Number of Products by Mechanism of Actions, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
        • Table Figure 29: Number of Products by Stage and Mechanism of Actions, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
        • Table Number of Products by Stage and Mechanism of Action, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Assessment by Route of Administration
        • Table Figure 30: Number of Products by Routes of Administration, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
        • Table Figure 31: Number of Products by Stage and Routes of Administration, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
        • Table Number of Products by Stage and Route of Administration, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Assessment by Molecule Type
        • Table Figure 32: Number of Products by Molecule Types, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
        • Table Figure 33: Number of Products by Stage and Molecule Types, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
        • Table Number of Products by Stage and Molecule Type, Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
    • Optic Neuritis
      • Assessment by Target
        • Table Figure 34: Number of Products by Targets, Optic Neuritis
        • Table Figure 35: Number of Products by Stage and Targets, Optic Neuritis
        • Table Number of Products by Stage and Target, Optic Neuritis
      • Assessment by Mechanism of Action
        • Table Figure 36: Number of Products by Mechanism of Actions, Optic Neuritis
        • Table Figure 37: Number of Products by Stage and Mechanism of Actions, Optic Neuritis
        • Table Number of Products by Stage and Mechanism of Action, Optic Neuritis
      • Assessment by Route of Administration
        • Table Figure 38: Number of Products by Routes of Administration, Optic Neuritis
        • Table Figure 39: Number of Products by Stage and Routes of Administration, Optic Neuritis
        • Table Number of Products by Stage and Route of Administration, Optic Neuritis
      • Assessment by Molecule Type
        • Table Figure 40: Number of Products by Molecule Types, Optic Neuritis
        • Table Figure 41: Number of Products by Stage and Molecule Types, Optic Neuritis
        • Table Number of Products by Stage and Molecule Type, Optic Neuritis
  • Companies Involved in Therapeutics Development
    • Optic Neuropathy
      • Amgen Inc
        • Table Optic Neuropathy – Pipeline by Amgen Inc, H2 2018
      • Ironwood Pharmaceuticals Inc
        • Table Optic Neuropathy – Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
      • Quark Pharmaceuticals Inc
        • Table Optic Neuropathy – Pipeline by Quark Pharmaceuticals Inc, H2 2018
      • Regenera Pharma Ltd
        • Table Optic Neuropathy – Pipeline by Regenera Pharma Ltd, H2 2018
      • Regeneron Pharmaceuticals Inc
        • Table Optic Neuropathy – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
    • Glaucoma
      • AC Immune SA
        • Table Glaucoma – Pipeline by AC Immune SA, H2 2018
      • Aerie Pharmaceuticals Inc
        • Table Glaucoma – Pipeline by Aerie Pharmaceuticals Inc, H2 2018
      • Allergan Plc
        • Table Glaucoma – Pipeline by Allergan Plc, H2 2018
      • Altacor Ltd
        • Table Glaucoma – Pipeline by Altacor Ltd, H2 2018
      • Amarantus Bioscience Holdings Inc
        • Table Glaucoma – Pipeline by Amarantus Bioscience Holdings Inc, H2 2018
      • Amgen Inc
        • Table Glaucoma – Pipeline by Amgen Inc, H2 2018
      • Annexon Inc
        • Table Glaucoma – Pipeline by Annexon Inc, H2 2018
      • Astellas Pharma Inc
        • Table Glaucoma – Pipeline by Astellas Pharma Inc, H2 2018
      • Bial - Portela & Ca SA
        • Table Glaucoma – Pipeline by Bial - Portela & Ca SA, H2 2018
      • BioAxone BioSciences Inc
        • Table Glaucoma – Pipeline by BioAxone BioSciences Inc, H2 2018
      • Can-Fite BioPharma Ltd
        • Table Glaucoma – Pipeline by Can-Fite BioPharma Ltd, H2 2018
      • Cellix Bio Pvt Ltd
        • Table Glaucoma – Pipeline by Cellix Bio Pvt Ltd, H2 2018
      • Certa Therapeutics Pty Ltd
        • Table Glaucoma – Pipeline by Certa Therapeutics Pty Ltd, H2 2018
      • Chong Kun Dang Pharmaceutical Corp
        • Table Glaucoma – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018
      • D. Western Therapeutics Institute Inc
        • Table Glaucoma – Pipeline by D. Western Therapeutics Institute Inc, H2 2018
      • Disarm Therapeutics Inc
        • Table Glaucoma – Pipeline by Disarm Therapeutics Inc, H2 2018
      • Dompe Farmaceutici SpA
        • Table Glaucoma – Pipeline by Dompe Farmaceutici SpA, H2 2018
      • Elsalys Biotech SA
        • Table Glaucoma – Pipeline by Elsalys Biotech SA, H2 2018
      • EyePoint Pharmaceuticals Inc
        • Table Glaucoma – Pipeline by EyePoint Pharmaceuticals Inc, H2 2018
      • Eyevensys SAS
        • Table Glaucoma – Pipeline by Eyevensys SAS, H2 2018
      • Fortress Biotech Inc
        • Table Glaucoma – Pipeline by Fortress Biotech Inc, H2 2018
      • Gene Signal International SA
        • Table Glaucoma – Pipeline by Gene Signal International SA, H2 2018
      • Glaukos Corp
        • Table Glaucoma – Pipeline by Glaukos Corp, H2 2018
      • Graybug Vision Inc
        • Table Glaucoma – Pipeline by Graybug Vision Inc, H2 2018
      • Han Wha Pharma Co Ltd
        • Table Glaucoma – Pipeline by Han Wha Pharma Co Ltd, H2 2018
      • Handok Inc
        • Table Glaucoma – Pipeline by Handok Inc, H2 2018
      • HitGen LTD
        • Table Glaucoma – Pipeline by HitGen LTD, H2 2018
      • ID Pharma Co Ltd
        • Table Glaucoma – Pipeline by ID Pharma Co Ltd, H2 2018
      • InMed Pharmaceuticals Inc
        • Table Glaucoma – Pipeline by InMed Pharmaceuticals Inc, H2 2018
      • Inspyr Therapeutics Inc
        • Table Glaucoma – Pipeline by Inspyr Therapeutics Inc, H2 2018
      • Isarna Therapeutics GmbH
        • Table Glaucoma – Pipeline by Isarna Therapeutics GmbH, H2 2018
      • Kowa Co Ltd
        • Table Glaucoma – Pipeline by Kowa Co Ltd, H2 2018
      • Kukje Pharmaceutical Industry Co Ltd
        • Table Glaucoma – Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2018
      • Laboratorios SALVAT SA
        • Table Glaucoma – Pipeline by Laboratorios SALVAT SA, H2 2018
      • Laboratorios Sophia SA de CV
        • Table Glaucoma – Pipeline by Laboratorios Sophia SA de CV, H2 2018
      • Lee's Pharmaceutical Holdings Ltd
        • Table Glaucoma – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
      • MimeTech Srl
        • Table Glaucoma – Pipeline by MimeTech Srl, H2 2018
      • Nemus Bioscience Inc
        • Table Glaucoma – Pipeline by Nemus Bioscience Inc, H2 2018
      • Neurim Pharmaceuticals Ltd
        • Table Glaucoma – Pipeline by Neurim Pharmaceuticals Ltd, H2 2018
      • NicOx SA
        • Table Glaucoma – Pipeline by NicOx SA, H2 2018
      • NoNO Inc
        • Table Glaucoma – Pipeline by NoNO Inc, H2 2018
      • Novaliq GmbH
        • Table Glaucoma – Pipeline by Novaliq GmbH, H2 2018
      • Novartis AG
        • Table Glaucoma – Pipeline by Novartis AG, H2 2018
      • Ocular Therapeutix Inc
        • Table Glaucoma – Pipeline by Ocular Therapeutix Inc, H2 2018
      • Oculis ehf
        • Table Glaucoma – Pipeline by Oculis ehf, H2 2018
      • Ohr Pharmaceutical Inc
        • Table Glaucoma – Pipeline by Ohr Pharmaceutical Inc, H2 2018
      • Oncolys BioPharma Inc
        • Table Glaucoma – Pipeline by Oncolys BioPharma Inc, H2 2018
      • Pivot Pharmaceuticals Inc
        • Table Glaucoma – Pipeline by Pivot Pharmaceuticals Inc, H2 2018
      • Profarma
        • Table Glaucoma – Pipeline by Profarma, H2 2018
      • Q BioMed Inc
        • Table Glaucoma – Pipeline by Q BioMed Inc, H2 2018
      • Quark Pharmaceuticals Inc
        • Table Glaucoma – Pipeline by Quark Pharmaceuticals Inc, H2 2018
      • Regeneron Pharmaceuticals Inc
        • Table Glaucoma – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
      • ReNetX Bio
        • Table Glaucoma – Pipeline by ReNetX Bio, H2 2018
      • Santen Pharmaceutical Co Ltd
        • Table Glaucoma – Pipeline by Santen Pharmaceutical Co Ltd, H2 2018
      • Senju Pharmaceutical Co Ltd
        • Table Glaucoma – Pipeline by Senju Pharmaceutical Co Ltd, H2 2018
      • Shire Plc
        • Table Glaucoma – Pipeline by Shire Plc, H2 2018
      • Sun Pharma Advanced Research Company Ltd
        • Table Glaucoma – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018
      • Sylentis SAU
        • Table Glaucoma – Pipeline by Sylentis SAU, H2 2018
      • Taejoon Pharm Co Ltd
        • Table Glaucoma – Pipeline by Taejoon Pharm Co Ltd, H2 2018
      • TikoMed AB
        • Table Glaucoma – Pipeline by TikoMed AB, H2 2018
      • Unity Biotechnology Inc
        • Table Glaucoma – Pipeline by Unity Biotechnology Inc, H2 2018
    • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Alkeus Pharmaceuticals Inc
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Alkeus Pharmaceuticals Inc, H2 2018
      • Bactevo Ltd
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Bactevo Ltd, H2 2018
      • Biovista Inc
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Biovista Inc, H2 2018
      • Fortify Therapeutics Inc
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Fortify Therapeutics Inc, H2 2018
      • GenSight Biologics SA
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by GenSight Biologics SA, H2 2018
      • Ixchel Pharma LLC
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Ixchel Pharma LLC, H2 2018
      • Khondrion BV
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Khondrion BV, H2 2018
      • Mitobridge Inc
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Mitobridge Inc, H2 2018
      • Mitotech SA
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Mitotech SA, H2 2018
      • Santhera Pharmaceuticals Holding AG
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Santhera Pharmaceuticals Holding AG, H2 2018
      • Spark Therapeutics Inc
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Spark Therapeutics Inc, H2 2018
      • Stealth BioTherapeutics Inc
        • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Pipeline by Stealth BioTherapeutics Inc, H2 2018
    • Optic Neuritis
      • Bionure Farma SL
        • Table Optic Neuritis – Pipeline by Bionure Farma SL, H2 2018
      • Commence Bio Inc
        • Table Optic Neuritis – Pipeline by Commence Bio Inc, H2 2018
      • Lipocure Ltd
        • Table Optic Neuritis – Pipeline by Lipocure Ltd, H2 2018
      • Meta-IQ ApS
        • Table Optic Neuritis – Pipeline by Meta-IQ ApS, H2 2018
      • Mitochon Pharmaceuticals Inc
        • Table Optic Neuritis – Pipeline by Mitochon Pharmaceuticals Inc, H2 2018
      • Teijin Pharma Ltd
        • Table Optic Neuritis – Pipeline by Teijin Pharma Ltd, H2 2018
  • Dormant Projects
    • Optic Neuropathy
      • Table Optic Neuropathy – Dormant Projects, H2 2018
    • Glaucoma
      • Table Glaucoma – Dormant Projects, H2 2018
    • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Table Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) –Dormant Projects, H2 2018
    • Optic Neuritis
      • Table Optic Neuritis – Dormant Projects, H2 2018
  • Discontinued Products
    • Optic Neuropathy
      • Table Optic Neuropathy – Discontinued Products, H2 2018
    • Glaucoma
      • Table Glaucoma – Discontinued Products, H2 2018
    • Optic Neuritis
      • Table Optic Neuritis – Discontinued Products, H2 2018
  • Product Development Milestones
    • Optic Neuropathy
      • Featured News & Press Releases
    • Glaucoma
      • Featured News & Press Releases
    • Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy)
      • Featured News & Press Releases
    • Optic Neuritis
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report